Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02950376
Other study ID # MZhao-006
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2016
Est. completion date December 2018

Study information

Verified date January 2020
Source Shanghai Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this research is to develop an objective assessment based on the virtual reality techniques which is used for evaluate addiction severity.


Description:

In order to evaluate the addiction severity and the effect of rehabilitation objectively, this study develops a virtual environment model based on the virtual reality technique, making the subjects in a drug related or neutral scene , at the same time recording the physical signs and eye movements index. Reliability and validity of this system will also be tested in this study. And we will construct the norm of addiction assessment system in Shanghai .The evaluating system will be very beneficial to develop novel and practical assessment for synthetic durg related disorder, and provide a reference for other drug dependence diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 1500
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Criteria for synthetic drug abusers:

Inclusion Criteria:

- In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-4) for methamphetamine (MA) use disorders;

- Education level equal or more than 9 years;

- Have normal or corrected-to-normal vision;

- Have normal or corrected-to-normal hearing;

- Less than 3 months before last drug use;

Exclusion Criteria:

- Current substance use (except nicotine or caffeine) ;

- History of disease which influence cognition,such as seizure disorder?cerebrovascular disease? head injury or other severe medication conditions;

- Intelligence quotient less than 70.

Criteria for healthy control:

Inclusion Criteria:

- Without schizophrenia family history;

- Without history of drug abuse;

- Education level equal or more than 9 years;

- Have normal or corrected-to-normal vision;

- Have normal or corrected-to-normal hearing.

Exclusion Criteria:

- History of disease which influence cognition,such as seizure disorder?cerebrovascular disease?head injury or other severe medication conditions;

- Intelligence quotient less than 70.

Study Design


Intervention

Other:
DSM-5 +Virtual reality-based addiction assessment system
The patients who used the amphetamine type stimulants will be diagnosed by the chief physician?associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate?galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl?3 months later? 6 months later and 1 year later and record the information synchronously.
Virtual reality-based addiction assessment system
The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate?galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
DSM-5 +Virtual reality-based addiction assessment system
The patients who used the amphetamine type stimulants will be diagnosed by the chief physician?associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate?galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of physiological indexs The physiological index including galvanic skin response?encephlogram and electromyogram will be used to evaluate the reliability and validity of the virtual reality based addiction assessment system, and construct the norms of assessment system as well. In 1 year
Primary Changes of eye movement index The eye movement index will be used to evaluate the reliability and validity of the virtual reality based addiction assessment system, and construct the norms of assessment system as well. In 1 year
Secondary The Diagnostic and Statistical Manual of Mental Disorders(DSM) To establish the criterion validity baseline
Secondary Addiction Severity Index(ASI) To establish the criterion validity baseline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05535101 - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder N/A
Not yet recruiting NCT02836756 - Cannabidiol as a New Intervention for Amphetamine Dependence Phase 2
Completed NCT03318081 - The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction N/A
Completed NCT03221283 - The Application of Music Therapy in Female Amphetamine Use Disorder N/A
Withdrawn NCT02952196 - Cannabioids as a New Intervention for Amphetamine Dependence Phase 2
Completed NCT02285556 - The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus N/A
Completed NCT02713815 - Novel Intervention for Amphetamine-type Stimulants Addiction N/A
Completed NCT00713479 - An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers Phase 1
Completed NCT04993300 - Repetitive Transcranial Magnetic Stimulation in Amphetamine Addiction N/A
Recruiting NCT04531384 - Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders. N/A
Recruiting NCT04687566 - Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction Phase 2/Phase 3